Shorter radiation with immunotherapy for stage II-III rectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a shorter course of radiation therapy that avoids lymph nodes, followed by an immunotherapy drug, for patients with stage II or III rectal cancer that has not spread. It aims to improve outcomes while reducing side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with rectal adenocarcinoma (a type of rectal cancer).
- Your tumor is located 5 to 10 cm from the anal verge (the opening of the anus).
- Your cancer is stage II or III and has not spread to distant organs (like the liver or lungs).
- Your cancer is pMMR or MSS (a specific genetic marker that may affect how well immunotherapy works).
- You have not had prior surgery (except a temporary colostomy), chemotherapy, or other anti-cancer treatment for this cancer.
- You have not had radiation therapy to the pelvic area before.
- You have adequate organ function (kidney, liver, blood counts) and are generally in good health (ECOG 0-1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a shorter course of radiation before chemotherapy and an immunotherapy drug to shrink mid-to-lower rectal cancer that has not spread. The goal is to improve treatment response and reduce side effects, potentially allowing for less invasive surgery.
This trial tests whether a short course of radiation followed by an immunotherapy drug (PD-L1 inhibitor) plus chemotherapy works as well as or better than a longer radiation course for locally advanced rectal cancer. The goal is to shrink tumors before surgery.
This study compares two treatment approaches for patients with locally advanced rectal cancer. One group gets a short course of radiation followed by chemotherapy combined with an immunotherapy drug called a PD-1 inhibitor, while the other group gets radiation and chemotherapy alone. The trial aims to see if the PD-1 inhibitor improves outcomes and whether a natural substance in the blood called beta-hydroxybutyrate can predict response.
This trial tests a new combination of short-course radiation, a targeted drug (fruquintinib), and an immunotherapy drug (PD-1 inhibitor) to treat rectal cancer before surgery. It aims to shrink the tumor and improve outcomes for patients with a specific type of rectal cancer.
This trial tests a new approach for locally advanced rectal cancer. You'll receive a short course of radiation, then chemotherapy plus an immunotherapy drug (a PD-1 inhibitor). The goal is to see if this combination shrinks the tumor enough to avoid surgery or improve outcomes.
This trial tests a treatment plan involving radiation, chemotherapy, and an immunotherapy drug (a PD-1 inhibitor) for people with a specific type of high-risk rectal cancer. The goal is to see if this combination helps shrink the tumor before surgery.
Hear when a new Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.